Logo image of CDTX

CIDARA THERAPEUTICS INC (CDTX) Stock Fundamental Analysis

NASDAQ:CDTX - Nasdaq - US1717572069 - Common Stock - Currency: USD

44.95  +23.93 (+113.84%)

After market: 44.9 -0.05 (-0.11%)

Fundamental Rating

3

Overall CDTX gets a fundamental rating of 3 out of 10. We evaluated CDTX against 558 industry peers in the Biotechnology industry. CDTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CDTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CDTX has reported negative net income.
In the past year CDTX has reported a negative cash flow from operations.
In the past 5 years CDTX always reported negative net income.
CDTX had a negative operating cash flow in each of the past 5 years.
CDTX Yearly Net Income VS EBIT VS OCF VS FCFCDTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

CDTX has a Return On Assets of -95.44%. This is in the lower half of the industry: CDTX underperforms 74.91% of its industry peers.
CDTX's Return On Equity of -129.15% is in line compared to the rest of the industry. CDTX outperforms 40.32% of its industry peers.
Industry RankSector Rank
ROA -95.44%
ROE -129.15%
ROIC N/A
ROA(3y)-61.33%
ROA(5y)-72.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CDTX Yearly ROA, ROE, ROICCDTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

CDTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDTX Yearly Profit, Operating, Gross MarginsCDTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

CDTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CDTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CDTX has been increased compared to 5 years ago.
CDTX has a better debt/assets ratio than last year.
CDTX Yearly Shares OutstandingCDTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CDTX Yearly Total Debt VS Total AssetsCDTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

CDTX has an Altman-Z score of -2.35. This is a bad value and indicates that CDTX is not financially healthy and even has some risk of bankruptcy.
CDTX's Altman-Z score of -2.35 is in line compared to the rest of the industry. CDTX outperforms 51.08% of its industry peers.
There is no outstanding debt for CDTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.35
ROIC/WACCN/A
WACC9.01%
CDTX Yearly LT Debt VS Equity VS FCFCDTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

CDTX has a Current Ratio of 3.87. This indicates that CDTX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CDTX (3.87) is comparable to the rest of the industry.
A Quick Ratio of 3.87 indicates that CDTX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.87, CDTX is in line with its industry, outperforming 46.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.87
Quick Ratio 3.87
CDTX Yearly Current Assets VS Current LiabilitesCDTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CDTX have decreased strongly by -41.54% in the last year.
Looking at the last year, CDTX shows a very negative growth in Revenue. The Revenue has decreased by -99.35% in the last year.
The Revenue for CDTX have been decreasing by -42.85% on average. This is quite bad
EPS 1Y (TTM)-41.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.19%
Revenue 1Y (TTM)-99.35%
Revenue growth 3Y-70.48%
Revenue growth 5Y-42.85%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, CDTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.99% on average per year.
The Revenue is expected to grow by 86.96% on average over the next years. This is a very strong growth
EPS Next Y34.47%
EPS Next 2Y12.44%
EPS Next 3Y8.63%
EPS Next 5Y13.99%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y86.96%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CDTX Yearly Revenue VS EstimatesCDTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2019 2020 2021 2022 2023 2024 2028 2029 2030 2031 2032 200M 400M 600M
CDTX Yearly EPS VS EstimatesCDTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CDTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDTX Price Earnings VS Forward Price EarningsCDTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDTX Per share dataCDTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.44%
EPS Next 3Y8.63%

More info and screens

0

5. Dividend

5.1 Amount

CDTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CIDARA THERAPEUTICS INC

NASDAQ:CDTX (6/23/2025, 4:04:51 PM)

After market: 44.9 -0.05 (-0.11%)

44.95

+23.93 (+113.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-11 2025-08-11
Inst Owners86.21%
Inst Owner Change25.96%
Ins Owners1.55%
Ins Owner Change0.98%
Market Cap583.00M
Analysts84.62
Price Target42.16 (-6.21%)
Short Float %3.72%
Short Ratio2.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.32%
Min EPS beat(2)-45.43%
Max EPS beat(2)54.07%
EPS beat(4)3
Avg EPS beat(4)27.47%
Min EPS beat(4)-45.43%
Max EPS beat(4)57.74%
EPS beat(8)5
Avg EPS beat(8)-100.7%
EPS beat(12)7
Avg EPS beat(12)-50.88%
EPS beat(16)10
Avg EPS beat(16)-16.71%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.77%
PT rev (3m)8.77%
EPS NQ rev (1m)18.83%
EPS NQ rev (3m)49.59%
EPS NY rev (1m)8.5%
EPS NY rev (3m)23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1930.47
P/FCF N/A
P/OCF N/A
P/B 4.11
P/tB 4.11
EV/EBITDA N/A
EPS(TTM)-10.87
EYN/A
EPS(NY)-8.45
Fwd EYN/A
FCF(TTM)-14.8
FCFYN/A
OCF(TTM)-14.79
OCFYN/A
SpS0.02
BVpS10.92
TBVpS10.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -95.44%
ROE -129.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.33%
ROA(5y)-72.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.9%
Cap/Sales 35.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.87
Quick Ratio 3.87
Altman-Z -2.35
F-Score2
WACC9.01%
ROIC/WACCN/A
Cap/Depr(3y)188.62%
Cap/Depr(5y)130.51%
Cap/Sales(3y)3.7%
Cap/Sales(5y)2.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-41.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.19%
EPS Next Y34.47%
EPS Next 2Y12.44%
EPS Next 3Y8.63%
EPS Next 5Y13.99%
Revenue 1Y (TTM)-99.35%
Revenue growth 3Y-70.48%
Revenue growth 5Y-42.85%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y86.96%
EBIT growth 1Y-182.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1107.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1117.02%
OCF growth 3YN/A
OCF growth 5YN/A